Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leucine-rich repeat-containing G protein-coupled receptor 6 (LGR6) is a member of the G protein-coupled receptor superfamily distinguished by 17 leucine-rich repeats flanked by cysteine-rich motifs in its large N-terminal extracellular domain. LGR6 serves as a high-affinity receptor for R-spondins 1–3, enhancing canonical Wnt/β-catenin signaling primarily through increased LRP6 phosphorylation. It is not coupled to canonical heterotrimeric G-protein signaling upon ligand binding. LGR6 identifies populations of multipotent stem cells in tissues such as skin and is involved in tissue regeneration and tumor suppression, with roles described in several cancers, and modulates cardiac hypertrophy via metabolic pathways[1][2][4][5][6][8].
Potentiation/activation of Wnt/β-catenin signaling (via R-spondin binding); Modulation of signaling pathways (including USP4-PPARα)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leucine-rich repeat-containing G protein-coupled receptor 6 (LGR6).